Platelet-Rich Plasma Therapy in the Treatment of Recalcitrant Melasma

Garg, Shilpa; Khillan, Kamini; Bharija, Subhash Chandra

doi:10.1097/dss.0000000000001559

Cited by 12 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The regression of melasma with PRP therapy has been reported by Garg and colleagues 4 where 2 patients of melasma underwent PRP therapy. The MASI score was 64 in the first patient and 47 in the second patient before starting PRP therapy.…”

Section: Discussionmentioning

confidence: 57%

“…2 Platelet-rich plasma (PRP) therapy has been reported to be beneficial in the treatment of chronic wounds, acne scars, alopecia, and photoageing and has shown its efficacy in the management of melasma. 3,4 In melasma, a high concentration of autologous platelets is prepared in a small volume of plasma and is delivered intradermally using microinjections. 5 However, there is paucity of studies on the use of PRP in melasma in a large sample size.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Role of Platelet-Rich Plasma Therapy as an Adjuvant in Treatment of Melasma

Bikash

Sarkar

Relhan

et al. 2022

View full text Add to dashboard Cite

BACKGROUND The management of melasma is an ongoing challenge. Platelet-rich plasma (PRP) therapy has been reported to be beneficial, but there is paucity of studies on PRP therapy in melasma. OBJECTIVE To compare the efficacy of PRP therapy and hydroquinone versus hydroquinone alone in melasma. MATERIALS AND METHODS Thirty patients were randomized to receive PRP microinjections on one side and normal saline on the other in a total of 3 sittings. Patients were concurrently advised 4% hydroquinone (HQ) cream application on both sides of the face. Efficacy was evaluated with hemi-modified Melasma Area Severity Index (MASI) scoring and a 4scale patient satisfaction grading. RESULTS Majority of the subjects (53.3%) in PRP + HQ group and 76.7% in HQ group had 25% to 50% improvement in their MASI scores. However, 40% in the PRP + HQ group and only 3.3% in the HQ group had 51% to 75% improvement. The difference in the percentage improvement was statistically significant. There was a greater percentage of subjects reporting a good response among the HQ + PRP group (53.3%) as compared with the HQ group (27%). CONCLUSION Microinjections of PRP combined with topical HQ has better efficacy than topical HQ alone.

show abstract

Section: Discussionmentioning

confidence: 57%

mentioning

confidence: 99%

Role of Platelet-Rich Plasma Therapy as an Adjuvant in Treatment of Melasma

Bikash

Sarkar

Relhan

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 19 Moreover, PRP has bacteriostatic, anti-inflammatory and repair functions that contribute to the metabolism of the abnormal hyperpigmentation observed in melasma. 20 …”

Section: Discussionmentioning

confidence: 99%

Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin

Zhang

Wu²,

Shen³

2022

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To investigate the effect of platelet-rich plasma (PRP) combined with tranexamic acid (TXA) in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor (VEGF), endothelin-1 (ET-1) and melanin stimulating hormone (MSH). Methods: We retrospectively analyzed clinical data of 80 patients with melasma treated in our hospital from January 2020 to June 2021. Patients (n=38) in the control group received simple oral TXA treatment. Patients (n=42) in the study group received PRP combined with oral TXA treatment. We assessed the treatment effects on the serum biochemical index levels, the adverse reactions, and the recurrence rates in the two groups. Results: The total efficacy of the study group (90.48%) was higher than that of the control group (73.68%) (p<0.05). After the treatment, the levels of serum VEGF increased and the levels of ET-1 and MSH decreased in both groups, but the changes in the study group were more pronounced than those in the control group (p<0.05). We found similar incidences of the adverse reaction in the study group (7.14%) and the control group (5.26%; p>0.05). The disease recurrence rates between the two groups three months after the treatment were similar (p>0.05). However, the disease recurrence rate in the study group (4.76%) was lower than that in the control group (21.05%) 6 months after treatment (p<0.05). Conclusions: PRP combined with oral TXA can improve the treatment effect of TXA alone in the treatment of melasma, maintaining normal levels of VEGF, ET-1 and MSH, reducing disease recurrences. doi: https://doi.org/10.12669/pjms.38.8.6786 How to cite this:Zhang C, Wu T, Shen N. Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin. Pak J Med Sci. 2022;38(8):2163-2168. doi: https://doi.org/10.12669/pjms.38.8.6786 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…Therefore, PRP is recommended as a safe and efficient strategy for facial skin rejuvenation [116]. Likewise, the applications of PRP started emerging in various skin diseases and disorders, including vitiligo [119][120][121][122][123], melasma [124,125], psoriasis [126], alopecia [5,[127][128][129][130][131], and inflammatory disorders [132].…”

Section: Skinmentioning

confidence: 99%

Recent advances in platelet-rich plasma and its derivatives: therapeutic agents for tissue engineering and regenerative medicine

Shome,

Kodieswaran,

Dadheech

et al. 2024

Prog. Biomed. Eng.

View full text Add to dashboard Cite

Platelet rich plasma (PRP) is a suspension of bioactive factors and chemokine enriched plasma. Platelets are a distinctive source of membrane bound and soluble proteins that are released upon their activation. The higher count of platelets renders PRP with an array of tissue regenerative abilities. PRP can be employed in the form of platelet containing plasma, platelet lysate plasma, or in the form of a pre-gelled fibrin matrix. PRP has been an essential alternative source of growth factors in the healing and regeneration of various tissues, such as musculoskeletal, cardiovascular, and dermal tissue, with additional applications in other tissues, such as hepatic and neural. A wide range of preparative and isolation strategies have been developed for various forms of PRP at laboratory and commercial scales. Concomitantly, PRP has found its applicability as an active component in several tissue regenerative approaches, including 3D printed/bioprinted constructs, injectable hydrogels, and crosslinked scaffolds. This review focuses on the various forms of PRP and their preparation methods, the latest tissue engineering applications of PRP, and the various tissue-specific clinical trials and findings conducted using PRP. We have further discussed the optimizations required in the methods of preparation, delivery, and long-term storage of PRP. Therefore, this review seeks to benefit the scope of research on PRP-based therapeutic agents in tissue engineering by providing comprehensive insights into the widespread application. We believe PRP could be instrumental in future patient-specific tissue engineering applications in both pre-clinical and clinical settings.

show abstract

Platelet-Rich Plasma Therapy in the Treatment of Recalcitrant Melasma

Cited by 12 publications

References 4 publications

Role of Platelet-Rich Plasma Therapy as an Adjuvant in Treatment of Melasma

Role of Platelet-Rich Plasma Therapy as an Adjuvant in Treatment of Melasma

Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin

Recent advances in platelet-rich plasma and its derivatives: therapeutic agents for tissue engineering and regenerative medicine

Contact Info

Product

Resources

About